News

Stories

See all

Updates: Lilly's Global COVID-19 Response

View Story

Lilly's COVID-19 Science Leads to a Second FDA Emergency Use Authorization

View Story

Time to Tear Down the Rebate Wall

View Story

When the World Called for Help with COVID-19, We Were Ready

View Story

Dave Ricks Shares About Lilly's FDA Emergency Use Authorization for a Neutralizing Antibody

View Story

An Update on Lilly’s Commitment to Quality Manufacturing

View Story


Press Releases

See all

Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

November 24, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19

November 20, 2020

Tags |  Product

- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use




Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 20, 2020

Tags |  Corporate

Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy   Precision will receive $100 million cash upfront and an equity investment by Lilly of $35




Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19

November 19, 2020

Tags |  Product

- ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment   - Authorization enables use of baricitinib in combination with remdesivir in hospitalized patients needing oxygen INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and